CD274 and neoplasm: In addition to well-known TIILs, TMB(49), clonal neoantigens (Robbins et al., 2013), and PD-L1 expression, newly identified signatures or algorithms, such as immunophenocscore (IPS) (Charoentong et al., 2017) and tumor immune dysfunction and exclusion (TIDE) (Roh et al., 2017; Fu et al., 2020), (Jiang et al., 2018), are widely used to predict response to immunotherapy.